OneMedNet Corp (NASDAQ: ONMD) shares surged 33% to $0.94 in after-hours trading on Tuesday after the healthcare data company announced an $11.5 million agreement to supply its regulatory-grade iRWD™ imaging data platform. The contract involves delivering de-identified medical imaging and clinical reports to train a foundational AI model, marking a significant commercial validation for the Minnesota-based firm. The stock had already closed the regular session up 17.79% at $0.71 before the late-day announcement triggered further buying interest.

The agreement centers on OneMedNet’s iRWD platform, which enables the secure, scalable delivery of multi-modal data optimized for AI training, regulatory submissions, and advanced analytics. Under the terms of the deal, OneMedNet will deliver de-identified medical imaging and clinical reports immediately. CEO Aaron Green stated that the deal validates the company’s ability to deliver “regulatory decision-grade Real-World Data at the scale and quality required for foundational AI model development.” Chairman Jeffrey Yu highlighted the platform’s built-in anonymization capabilities, which allow for live, longitudinal healthcare data access.

Network Scale and Market Position

OneMedNet emphasized that its provider network spans over 90 million patient journeys and 270 million clinical studies across more than 2,300 healthcare sites. This extensive infrastructure underscores the scale behind the new AI data deal. The company operates in a sector where data quality and regulatory compliance are critical barriers to entry, positioning its real-world data assets as valuable inputs for artificial intelligence development.

Trading Metrics and Technical Outlook

Despite the positive catalyst, OneMedNet faces a challenging technical backdrop. The company has a market capitalization of $40.11 million. Over the past 12 months, the stock has risen by 47.71%, but it is currently trading near its 52-week low of $0.44, with a 52-week high of $4.22. Benzinga’s Edge Stock Rankings indicate that ONMD has a negative price trend across all time frames. The Relative Strength Index (RSI) stands at 53.54, suggesting neutral momentum despite the recent volatility.

Corporate Governance Updates

In separate corporate governance news, OneMedNet disclosed in a Securities and Exchange Commission filing that its 2026 Annual Meeting of Stockholders is scheduled for Sept. 18. The stockholder record date for this meeting is set for Aug. 11. These dates are critical for shareholders wishing to vote on agenda items at the upcoming annual meeting.

What the Numbers Show

The juxtaposition of a significant revenue-generating contract against a negative long-term price trend highlights a divergence between fundamental developments and market sentiment. While the $11.5 million deal validates the commercial viability of OneMedNet’s data platform, the stock’s proximity to its 52-week low suggests investors remain cautious about near-term execution or broader market conditions affecting small-cap healthcare data firms. The immediate delivery of data under the agreement provides a tangible near-term revenue stream, potentially altering the risk profile for holders of ONMD shares.

OneMedNet filed a prospectus related to the offer and resale of up to 11.68M shares of common stock by the selling stockholders. The document outlines the specifics of the proposed transaction involving the company's equity securities.

The prospectus provides regulatory disclosure regarding the shares being offered by the selling stockholders. This filing constitutes the formal registration statement required for the resale of the securities.

Key Details of the Filing

The submission to the SEC covers the mechanics of the share distribution. The offering involves existing shareholders rather than newly issued stock by the company.

The prospectus serves as the primary disclosure document for potential investors reviewing the resale of these shares.